Guanosine

Guanosine

SCHEMBL4625995

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1.Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1.O=P(O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.68
TGM2 P21980 1/20 0.68
KRAS P01116 4/20 0.64
HPGD P15428 1/20 0.63
FUT5 Q11128 1/20 0.63
HINT1 P49773 1/20 0.60
P2RY2 P41231 2/20 0.59
P2RY4 P51582 1/20 0.59
P2RY6 Q15077 1/20 0.59
P2RX3 P56373 1/20 0.58
IMPDH2 P12268 5/20 0.57
IMPDH1 P20839 1/20 0.57
GSK3A P49840 2/20 0.57
RPS6KA3 P51812 2/20 0.57
MAPK14 Q16539 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanosine SCHEMBL19211836 1.00 NT5E (0.68) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL30125158 1.00 NT5E (0.68) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL6066347 0.99 NT5E (0.69) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL9827513 0.99 NT5E (0.69) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL30589987 0.99 NT5E (0.69) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL37404 0.96 NT5E (0.70) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL27797461 0.96 NT5E (0.70) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL4410882 0.95 TGM2 (0.65) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL22134208 0.95 NT5E (0.69) NT5ETGM2KRASHPGDFUT5
Guanosine SCHEMBL29046528 0.95 TGM2 (0.64) NT5ETGM2KRASHPGDFUT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021027-A1 POLYPEPTIDE COSMETIC COMPOSITIONS ELC MANAGEMENT LLC (US) 2026-01-22 US claimed
CN-119097693-A Biological peptide antibacterial tablet and preparation method thereof 广州绿人生物科技有限公司 2024-12-10 CN claimed
CN-118702745-A Preparation and application of diguanosine tetraphosphate 杭州合碳创物科技有限公司 2024-09-27 CN claimed
CN-115844804-B Composition for improving exogenous aging and preparation method and application thereof 湖北省吉美化妆品有限公司 2024-07-02 CN claimed
EP-4389214-A2 USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN Thorel, Jean-Noël (FR) 2024-06-26 EP claimed
EP-3466419-B1 USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN THOREL JEAN NOEL (FR) 2024-05-08 EP claimed
CN-116687793-A Use of myristyl nicotinate in cosmetics 杭州睿研前瞻生物科技有限公司 2023-09-05 CN claimed
CN-114795996-B Composition containing nucleoside components and application thereof 广东先强药业有限公司 2023-08-29 CN claimed
CN-115813803-A Composition capable of improving skin anti-wrinkle, moisturizing and whitening effects on cell layer 广州时光之城科技有限公司 2023-03-21 CN claimed
CN-114795996-A Composition containing nucleoside components and application thereof 广东先强药业有限公司 2022-07-29 CN claimed
EP-3142682-B1 ASSOCIATION OF A TETRAPEPTIDE AND A GLYCERYL ESTER FOR TREATING ANDROGENIC ALOPECIA FABRE PIERRE DERMO COSMETIQUE (FR) 2018-11-28 EP claimed
EP-1581177-B1 CUTANEOUS METABOLIC BIO-ACTIVATOR THOREL JEAN NOEL (FR) 2018-04-11 EP claimed
EP-1480610-B1 USE OF A HSP INDUCING COMPOUND TO LIMIT SECONDARY EFFECTS OF RETINOIDS SOC EXTRACTION PRINCIPES ACTIF (FR) 2008-01-09 EP claimed
EP-1025835-B1 Cosmetic composition for protecting the scalp from free radicals COTY BV (NL) 2005-03-23 EP claimed
EP-1049455-B1 COSMETIC PRODUCT BASED ON ARTEMIA SALINA EXTRACTS FOR REGENERATING AND STIMULATING SKIN CELLS COTY BV (NL) 2001-08-16 EP claimed
EP-1049455-A1 COSMETIC PRODUCT BASED ON ARTEMIA SALINA EXTRACTS FOR REGENERATING AND STIMULATING SKIN CELLS Coty B.V. (NL) 2000-11-08 EP claimed
EP-1025835-A2 Cosmetic composition for protecting the scalp from free radicals Coty B.V. (NL) 2000-08-09 EP claimed
WO-1999038483-A1 COSMETIC PRODUCT BASED ON ARTEMIA SALINA EXTRACTS FOR REGENERATING AND STIMULATING SKIN CELLS COTY B.V. (NL) 1999-08-05 WO claimed
US-20260021027-A1 POLYPEPTIDE COSMETIC COMPOSITIONS ELC MANAGEMENT LLC (US) 2026-01-22 US disclosed
WO-1999038483-A1 COSMETIC PRODUCT BASED ON ARTEMIA SALINA EXTRACTS FOR REGENERATING AND STIMULATING SKIN CELLS COTY B.V. (NL) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021027-A1 POLYPEPTIDE COSMETIC COMPOSITIONS CUTA, SPPL2B, SPPL2A NT5E 308/4885TGM2 177/4885KRAS 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.